Evidence map›Paper›PMID 35966085›Full record

Trial reportFrontiers in endocrinology2022

Obesity and clinical outcomes in COVID-19 patients without comorbidities, a

Peng Yu, Ziqi Tan, Zhangwang Li, Yi Xu, Jing Zhang, Panpan Xia, Xiaoyi Tang, Jianyong Ma, Minxuan Xu, Xiao Liu and 1 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Repurposing of Chemotherapeutics to Combat COVID-19.Current topics in medicinal chemistry · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Peng YuDepartment of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Ziqi TanDepartment of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Zhangwang LiThe Second Clinical Medical College of Nanchang University, Nanchang, China.
Yi XuDepartment of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Jing ZhangThe Second Clinical Medical College of Nanchang University, Nanchang, China.
Panpan XiaDepartment of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Xiaoyi TangDepartment of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Jianyong MaDepartment of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Minxuan XuDepartment of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Xiao LiuInstitute for the Study of Endocrinology and Metabolism in Jiangxi Province, Nanchang, China.
Yunfeng ShenDepartment of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Second Affiliated Hospital of Nanchang University · CNNanchang University · CNUniversity of Cincinnati Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Large body of studies described individuals with obesity experiencing a worse prognosis in COVID-19. However, the effects of obesity on the prognosis of COVID-19 in patients without comorbidities have not been studied. Therefore, the current study aimed to provide evidence of the relationship between obesity and clinical outcomes in COVID-19 patients without comorbidities. Methods: A total of 116 hospitalized COVID-19 patients without comorbidities from the ORCHID study (Patients with COVID-19 from the Outcomes Related to COVID-19 Treated with Hydroxychloroquine among Inpatients with Symptomatic Disease) were included. Obesity is defined as a BMI of ≥30 kg/m Results: The percentage of obesity in COVID-19 patients without comorbidities was 54.3% (63/116). Discharge at 28 days occurred in 56/63 (84.2%) obese and 51/53 (92.2%) non-obese COVID-19 patients without comorbidities. Four (3.4%) COVID-19 patients without any comorbidities died within 28 days, among whom 2/63 (3.2%) were obese and 2/53 (3.8%) were non-obese. Multivariate Cox regression analyses showed that obesity was independently associated with a decreased rate of 28-day discharge (adjusted Conclusions: Obesity was independently linked to prolonged hospital length of stay in COVID-19 without any comorbidity. Larger prospective trials are required to assess the role of obesity in COVID-19 related deaths.

Indexed as

COVID-19ComorbidityHumansObesityProportional Hazards ModelsProspective StudiescomorbiditiesCOVID-19deathdischargeobesity

Identifiers

PMID35966085
PMCPMC9372447
OpenAlexW4288488989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.